Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX) has announced that its CEO, Jeffrey Stein, Ph.D., will present virtually at the Raymond James Human Health Innovations Conference on June 18, 2020, at 3:40 PM ET. The company focuses on developing long-acting therapeutic solutions for serious fungal and viral infections. Notably, Cidara is advancing its lead Phase 3 antifungal candidate, rezafungin, along with antiviral conjugates from its Cloudbreak antiviral platform. Investors can access the live webcast on the company's website.
Details
News Market Reaction – CDTX
The recorded move for CDTX in the trading session of this news was -10.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present virtually at the Raymond James Human Health Innovations Conference on Thursday, June 18, 2020.
| Presentation Information: | ||
| Date: | Thursday, June 18, 2020 | |
| Time: | 3:40 PM ET | |
| Webcast: | A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com. |
About Cidara Therapeutics
Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Karen O’Shea, Ph.D.
LifeSci Communications
(929) 469-3860
koshea@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.